Novartis: Diarrhea trials
The registry lists 13 Diarrhea studies with Novartis as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 2 6Phase 3 4Phase 4 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.CompletedNCT04321460Phase 3Results posted
- Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066CompletedNCT03198767Phase 2Results posted
- A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.TerminatedNCT02920242Phase 3Results posted
- To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.CompletedNCT02713243Phase 2Results posted
- Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast CancerTerminatedNCT02294786Phase 2Results posted
- An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's DiseaseTerminatedNCT01009281Phase 2Results posted
- Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced DiarrheaCompletedNCT00582426Phase 3Results posted
- Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)CompletedNCT00699166Phase 2
- Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)CompletedNCT00394173Phase 2
- STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced DiarrheaCompletedNCT00050635Phase 4
- Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon CancerTerminatedNCT00006269Phase 3
- A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.CompletedNCT00002253Not applicable
- A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related DiarrheaCompletedNCT00002252Not applicable